Theriva Biologics
TOVX
20 hedge funds and large institutions have $479K invested in Theriva Biologics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0.03% less ownership
Funds ownership: 0.29% → 0.27% (-0.03%)
17% less funds holding
Funds holding: 24 → 20 (-4)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
58% less capital invested
Capital invested by funds: $1.15M → $479K (-$672K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$12K |
| 2 |
Renaissance Technologies
New York
|
+$581 |
| 3 |
Morgan Stanley
New York
|
+$272 |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$218 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$55K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$31K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$18K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.51K |
TOVX Hedge Fund Activity: Q4 2022 in Review
20 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2022, worth a combined $479K — down 58% from $1.15M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TOVX and 1 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Virtu Financial, adding an estimated $12K. The largest seller was Citadel Advisors, exiting entirely with an estimated $55K sold.
- 20 institutional investors held Theriva Biologics (TOVX) as of Q4 2022, down from 24 in Q3 2022.
- Funds reported $479K of Theriva Biologics stock for Q4 2022, down 58% quarter-over-quarter.
- 1 fund opened new Theriva Biologics positions in Q4 2022 and 5 closed out, a net change of -4 holders.
- The largest Theriva Biologics buyer in Q4 2022 was Virtu Financial, an estimated $12K added.
- The largest Theriva Biologics seller in Q4 2022 was Citadel Advisors, an estimated $55K sold.
Based on aggregated 13F filings for Q4 2022.